On December 15, 2015, the US FDA approved the Dutch company Organon's new drug Sugammadex under the trade name Bridion through the priority approval pathway. It is used to rapidly reverse neurochemicalbook muscle block induced by anesthesia rocuronium and vecuronium during surgery in adult patients. Sulgamose is a synthetic modified gamma-cyclodextrin consisting of a lipophilic core and a hydrophilic outer end. The intravenous administration of Sugamose can significantly improve the recovery of muscle relaxants after surgery, and the rapid reversal of the neuromuscular blocking effect of steroid muscle relaxants in a short period of time has positive significance for improving the safety of general anesthesia.